Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Shauna Lambe"'
Autor:
Gerard P. Quinn, Tamas Sessler, Baharak Ahmaderaghi, Shauna Lambe, Harper VanSteenhouse, Mark Lawler, Mark Wappett, Bruce Seligmann, Daniel B. Longley, Simon S. McDade
Publikováno v:
BMC Bioinformatics, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Background Transcriptionally informed predictions are increasingly important for sub-typing cancer patients, understanding underlying biology and to inform novel treatment strategies. For instance, colorectal cancers (CRCs) can be classified
Externí odkaz:
https://doaj.org/article/c0829fc0ca034492a1c3d272aaaac828
Autor:
Sandra Van Schaeybroeck, Sarah Ross, Melissa J. LaBonte, Chris Winnington, Jose Sousa, Jochen H.M. Prehn, Andreas U. Lindner, Manisha Maurya, Shauna Lambe, Christopher J. Scott, Simon S. McDade, Frederica Di Nicolantonio, Alberto Bardelli, Lyndsey Hanson, Daryl Griffin, Mustasin Rassel, Cheryl H. Latimer, Rebecca Briggs, Hajrah Khawaja
concentrations of drugs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::775d1337fd04e2390f5c609136da2ed2
https://doi.org/10.1158/1535-7163.22523058
https://doi.org/10.1158/1535-7163.22523058
Autor:
Sandra Van Schaeybroeck, Sarah Ross, Melissa J. LaBonte, Chris Winnington, Jose Sousa, Jochen H.M. Prehn, Andreas U. Lindner, Manisha Maurya, Shauna Lambe, Christopher J. Scott, Simon S. McDade, Frederica Di Nicolantonio, Alberto Bardelli, Lyndsey Hanson, Daryl Griffin, Mustasin Rassel, Cheryl H. Latimer, Rebecca Briggs, Hajrah Khawaja
antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ba82bc4493ab5ff598581035f75294
https://doi.org/10.1158/1535-7163.22523061.v1
https://doi.org/10.1158/1535-7163.22523061.v1
Autor:
Sandra Van Schaeybroeck, Sarah Ross, Melissa J. LaBonte, Chris Winnington, Jose Sousa, Jochen H.M. Prehn, Andreas U. Lindner, Manisha Maurya, Shauna Lambe, Christopher J. Scott, Simon S. McDade, Frederica Di Nicolantonio, Alberto Bardelli, Lyndsey Hanson, Daryl Griffin, Mustasin Rassel, Cheryl H. Latimer, Rebecca Briggs, Hajrah Khawaja
Supplementary materials and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c21fbe5dae3da4aeff204b4c1e853aa
https://doi.org/10.1158/1535-7163.22523052.v1
https://doi.org/10.1158/1535-7163.22523052.v1
Autor:
Sandra Van Schaeybroeck, Sarah Ross, Melissa J. LaBonte, Chris Winnington, Jose Sousa, Jochen H.M. Prehn, Andreas U. Lindner, Manisha Maurya, Shauna Lambe, Christopher J. Scott, Simon S. McDade, Frederica Di Nicolantonio, Alberto Bardelli, Lyndsey Hanson, Daryl Griffin, Mustasin Rassel, Cheryl H. Latimer, Rebecca Briggs, Hajrah Khawaja
Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2546072b012549475335793c8492b489
https://doi.org/10.1158/1535-7163.c.6543573.v1
https://doi.org/10.1158/1535-7163.c.6543573.v1
Autor:
Sandra Van Schaeybroeck, Sarah Ross, Melissa J. LaBonte, Chris Winnington, Jose Sousa, Jochen H.M. Prehn, Andreas U. Lindner, Manisha Maurya, Shauna Lambe, Christopher J. Scott, Simon S. McDade, Frederica Di Nicolantonio, Alberto Bardelli, Lyndsey Hanson, Daryl Griffin, Mustasin Rassel, Cheryl H. Latimer, Rebecca Briggs, Hajrah Khawaja
Supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3ba2360c48ca0e88a206ec47a1cb8f7
https://doi.org/10.1158/1535-7163.22523055
https://doi.org/10.1158/1535-7163.22523055
Autor:
Sharon A Glynn, Dibyangana Bhattacharyya, Shauna Lambe, Emma Kerr, Simon McDade, Faizan H Khan, Eoin Dervan, Feng Wang-Johanning, Sean Hynes, Grace Callagy
Publikováno v:
Cancer Research. 82:P3-06
Background: Human endogenous retrovirus K (HERV-K) belongs to a family of endogenous retroviruses that are present in our genome with similarities to present day exogenous retroviruses. HERV-K, like other endogenous retroviruses, is transmitted verti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2047c58feca104db59a8730934c2837a
https://doi.org/10.1158/1538-7445.sabcs21-p3-06-05
https://doi.org/10.1158/1538-7445.sabcs21-p3-06-05
Autor:
Hajrah Khawaja, Rebecca Briggs, Cheryl H. Latimer, Mustasin Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Frederica Di Nicolantonio, Simon S. McDade, Christopher J. Scott, Shauna Lambe, Manisha Maurya, Andreas U. Lindner, Jochen H.M. Prehn, Jose Sousa, Chris Winnington, Melissa J. LaBonte, Sarah Ross, Sandra Van Schaeybroeck
Publikováno v:
Khawaja, H, Briggs, R, Latimer, C H, Rassel, M, Griffin, D, Hanson, L, Bardelli, A, Di Nicolantonio, F, McDade, S S, Scott, C J, Lambe, S, Maurya, M, Lindner, A U, Prehn, J H M, Sousa, J, Winnington, C, LaBonte, M J, Ross, S & Van Schaeybroeck, S 2023, ' Bcl-xL is a key mediator of apoptosis following KRAS G12C inhibition in KRAS G12C-mutant colorectal cancer ', Molecular Cancer Therapeutics, vol. 22, no. 1, pp. 135–149 . https://doi.org/10.1158/1535-7163.mct-22-0301
Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Small-molec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b03203b5408aea5f0c7e4b9ff2129c
https://hdl.handle.net/2318/1888885
https://hdl.handle.net/2318/1888885
Autor:
Hajrah Khawaja, Rebecca Briggs, Cheryl Latimer, Md A.M.B. Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Frederica Di Nicolantonio, Simon McDade, Christopher J. Scott, Shauna Lambe, Manisha Maurya, Andreas Lindner, Jochen H.M. Prehn, Jose Sousa, Chris Winnington, Melissa J. LaBonte, Sarah Ross, Sandra Van Schaeybroeck
PurposeNovel covalent inhibitors of KRASG12C have shown limited response rates in KRASG12C mutant (MT) colorectal cancer (CRC) patients. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed.Expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e05cc0434d4a98b37da0af7e86458e2a
https://doi.org/10.1101/2022.05.10.491367
https://doi.org/10.1101/2022.05.10.491367
Autor:
Hajrah Khawaja, Rebecca Briggs, Cheryl Latimer, Md A.M.B Rassel, Daryl Griffin, Lyndsey Hanson, Alberto Bardelli, Federica Di Nicolantonio, Simon McDade, Christopher Scott, Shauna Lambe, Manisha Maurya, Andreas Ulrich Lindner, Jochen HM Prehn, Jose Sousa, Chris Winnington, Melissa J LaBonte, Sarah Ross, Sandra Van Schaeybroeck
Publikováno v:
Journal of Clinical Oncology. 40:3557-3557
3557 Background: Novel covalent inhibitors of KRASG12C have shown modest response rates in KRASG12C mutant (MT) colorectal cancer (CRC) patients. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd65836cf76e388783591fb28c99b175
https://doi.org/10.1200/jco.2022.40.16_suppl.3557
https://doi.org/10.1200/jco.2022.40.16_suppl.3557